casdatifan
-
ARC-20 Study Reveals Promising Results for Casdatifan and Cabozantinib in Metastatic Kidney Cancer
Arcus Biosciences’ shares surged after promising Phase 1/1b data for its casdatifan-cabozantinib combo in clear cell renal cell carcinoma (ccRCC. The ARC-20 study showed a 46% confirmed overall response rate, exceeding historic benchmarks. Arcus plans Phase 3 trials (PEAK-1) and others evaluating the combination in various ccRCC treatment settings. The positive results highlight the potential to change standards of care for patients whose ccRCC has advanced despite prior immunotherapy treatment.
